MX2021001783A - Agentes inhibidores de ask1. - Google Patents

Agentes inhibidores de ask1.

Info

Publication number
MX2021001783A
MX2021001783A MX2021001783A MX2021001783A MX2021001783A MX 2021001783 A MX2021001783 A MX 2021001783A MX 2021001783 A MX2021001783 A MX 2021001783A MX 2021001783 A MX2021001783 A MX 2021001783A MX 2021001783 A MX2021001783 A MX 2021001783A
Authority
MX
Mexico
Prior art keywords
inhibiting agents
ask1
compounds
formula
ask1 inhibiting
Prior art date
Application number
MX2021001783A
Other languages
English (en)
Inventor
Lopez De Turiso Felix Gonzalez
Zhili Xin
John H Jones
Martin Himmelbauer
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2021001783A publication Critical patent/MX2021001783A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan compuestos de Fórmula (I) (ver formula) incluidos compuestos de Fórmulas (II), (III), (IV), (V) y (VI), en donde X, R1, R2, R3, R4 y n son como se definen en el presente documento, y sales farmacéuticamente aceptables de los mismos y métodos para su uso y producción; estos compuestos pueden ser útiles, por ejemplo, en el tratamiento de trastornos que responden a la inhibición de la quinasa 1 reguladora de la señal de apoptosis (ASK1).
MX2021001783A 2018-08-14 2019-08-13 Agentes inhibidores de ask1. MX2021001783A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862718622P 2018-08-14 2018-08-14
PCT/US2019/046334 WO2020036949A1 (en) 2018-08-14 2019-08-13 Ask1 inhibiting agents

Publications (1)

Publication Number Publication Date
MX2021001783A true MX2021001783A (es) 2021-08-11

Family

ID=67777431

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001783A MX2021001783A (es) 2018-08-14 2019-08-13 Agentes inhibidores de ask1.

Country Status (12)

Country Link
US (1) US20210317103A1 (es)
EP (1) EP3837251B1 (es)
JP (1) JP2021534152A (es)
CN (1) CN113227070A (es)
AU (1) AU2019321412A1 (es)
BR (1) BR112021002690A2 (es)
CA (1) CA3109504A1 (es)
CO (1) CO2021003218A2 (es)
ES (1) ES2963122T3 (es)
MA (1) MA53225A (es)
MX (1) MX2021001783A (es)
WO (1) WO2020036949A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO2005040152A1 (en) * 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Heteroyclylphenyl-and heterocyclylpyridyl-substituted azolecarboxamides as herbicides
US7756674B2 (en) * 2007-08-03 2010-07-13 The Trustees Of Columbia University In The City Of New York Methods of calculating differences of binding affinities between congeneric pairs of ligands by way of a displaced solvent functional
EP2271646A1 (en) * 2008-03-31 2011-01-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
WO2010008843A1 (en) * 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
UY32146A (es) * 2008-09-29 2010-04-30 Boehringer Ingelheim Int Derivados de las 5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-nicotinamidas n-(sustituidas) y de las n-{5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-piridin-3-il}-benzamidas sustituidas y composiciones conteniéndolos
TWI491606B (zh) * 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
WO2011041293A1 (en) * 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
US8802695B2 (en) * 2010-02-03 2014-08-12 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
KR101759759B1 (ko) * 2010-07-02 2017-07-19 길리애드 사이언시즈, 인코포레이티드 세포자멸사 신호-조절 키나아제 저해제
CN114907358A (zh) * 2021-02-09 2022-08-16 上海翰森生物医药科技有限公司 含吡啶多环类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
CO2021003218A2 (es) 2021-03-29
EP3837251A1 (en) 2021-06-23
EP3837251B1 (en) 2023-06-21
ES2963122T3 (es) 2024-03-25
AU2019321412A1 (en) 2021-03-04
MA53225A (fr) 2021-06-23
CA3109504A1 (en) 2020-02-20
JP2021534152A (ja) 2021-12-09
WO2020036949A8 (en) 2020-09-10
CN113227070A (zh) 2021-08-06
US20210317103A1 (en) 2021-10-14
WO2020036949A1 (en) 2020-02-20
BR112021002690A2 (pt) 2021-05-11

Similar Documents

Publication Publication Date Title
MX2023001876A (es) Derivados de rapamicina.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12017501326A1 (en) Tgf-� inhibitors
PH12016502168A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
PH12019502334A1 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2019012336A (es) Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
MD20160053A2 (ro) Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
MX2020009062A (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos.
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
MX2020010181A (es) Compuestos de piperidina como inhibidores covalentes de menina.
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
NZ734260A (en) Substituted triazoles and methods relating thereto
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
PH12019501171A1 (en) Pyrido [3, 4-d] pyrimidine derivative and pharmaceutically acceptable salt thereof
JOP20210275A1 (ar) مشتقات 3-أمينو-4h-بنزو[e][4,2,1]ثيادايازين 1,1-داي أكسيد كمثبطات لـ mrgx2
MX2019010756A (es) Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
JOP20200318A1 (ar) عوامل تثبيط ask1